Romidepsin in relapsed/refractory T-cell lymphomas: Italian experience and results of a named patient program.

MLA

Zinzani, Pier Luigi, et al. “Romidepsin in Relapsed/Refractory T-Cell Lymphomas: Italian Experience and Results of a Named Patient Program.” Leukemia & Lymphoma, vol. 57, no. 10, Oct. 2016, pp. 2370–74. EBSCOhost, https://doi.org/10.3109/10428194.2015.1137292.

APA

Zinzani, P. L., Pellegrini, C., Cerciello, G., Monaco, F., Volpetti, S., Peli, A., Angelucci, E., Corradini, P., Cox, M. C., Guarini, A., Musso, M., Bresciani, P., Amato, G., Billio, A., Caparrotti, G., Figuera, A., Nassi, L., Gaudio, F., Grossi, A., … Argnani, L. (2016). Romidepsin in relapsed/refractory T-cell lymphomas: Italian experience and results of a named patient program. Leukemia & Lymphoma, 57(10), 2370–2374. https://doi.org/10.3109/10428194.2015.1137292

Chicago

Zinzani, Pier Luigi, Cinzia Pellegrini, Giuseppe Cerciello, Federico Monaco, Stefano Volpetti, Annalisa Peli, Emanuele Angelucci, et al. 2016. “Romidepsin in Relapsed/Refractory T-Cell Lymphomas: Italian Experience and Results of a Named Patient Program.” Leukemia & Lymphoma 57 (10): 2370–74. doi:10.3109/10428194.2015.1137292.